 |
|
 |
 |
|
||||||||||||||
|
Zimulti is the New Name for Diet Drug Acomplia for U.S. market 4 April 2007 Finally Sanofi-Aventis, developer of Acomplia (Rimonabant), has come up with a new name Zimulti for Acomplia for the US market. Though, the drug is still stuck at the FDA for its approval. However, Acomplia is already up for grab in various European nations, Argentina and in Mexico. The FDA advisory panel is expected to air the positive and negative effects of According on June 13th. According to the meeting notice published by the FDA Endocrinologic and Metabolic Drugs Advisory Committee, it seemed it might make it clear suggestions made by some of Sanofi's financial analysts that the FDA may now approve Acomplia / Zimulti for treatment of type 2 diabetes. According to the report, the FDA would consider Rimonabant as an addition to diet and exercise for controlling obesity in people with a body mass index (BMI) equal to or greater than 30, or a body mass index (BMI) equal to or greater than 27 if they are suffering from at least one cardiovascular ailment. It doesn't look like a treatment for diabetes nor does it indicates as a treatment for metabolic syndrome. There is also one question related with the US insurers whether
they will agree to pay for the diet drug if FDA approves obesity
management. |
||||||||||||||
